CBLL CERIBELL INC.

Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

—Ms. Rodenbush to lead hiring and talent development initiatives—

—Mr. Price to focus on market development and penetration—

SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team.

“Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing functions will help us strategically expand our growing team and commercial footprint as we focus on bringing our AI-powered point-of-care EEG neurodiagnostic system to even more hospitals, providing benefit to more patients and providers,” said Jane Chao, Ph.D., co-founder and CEO of Ceribell. “The magnitude of the unmet need we are addressing is massive: up to one-third of ICU patients are at risk for nonconvulsive seizures. We are proud of our market penetration to date, but there is a significant opportunity for continued growth. Ms. Rodenbush and Mr. Price are important additions to our team, and will play key roles in driving our vital growth initiatives.”

Kristie Rodenbush, Chief People Officer

Ms. Rodenbush will oversee Ceribell’s People & Culture team. She has more than 25 years of human resources and talent management experience which spans various industries and includes roles at companies ranging from startups to publicly traded, international organizations. Most recently, she served as Chief People Officer of Meltwater, where she led human resources functions for more than 2,400 employees located in 30 countries. Ms. Rodenbush holds a Bachelor of Arts in Psychology from the University of California, San Diego.

Brian Price, Senior Vice President of Marketing

Mr. Price is an industry veteran who brings to Ceribell more than 25 years of experience in the medical device industry, including marketing leadership roles at Medtronic and Abbott. In his new role at Ceribell, he will leverage his expertise in market development, product portfolio planning, business development, health economics, reimbursement and sales. He most recently served as Chief Marketing Officer of VitalConnect, and previously held sales and marketing leadership roles with LivaNova, St. Jude Medical, WebMD and Guidant Corporation, where he drove multiple incremental product launches and disruptive therapy platforms across many specialties including neurology, cardiology, urology and gynecology. Mr. Price holds a Master of Business Administration degree from the University of Minnesota Carlson School of Management and a Bachelor of Science in Organizational Leadership and Industrial Technology from Purdue University.

About CeriBell Inc. 

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit  or follow the company on .

MEDIA CONTACT 

Corrie Rose

 

INVESTOR CONTACTS

Brian Johnston 

Laine Morgan

 



EN
19/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERIBELL INC.

 PRESS RELEASE

Ceribell Reports Second Quarter 2025 Financial Results

Ceribell Reports Second Quarter 2025 Financial Results SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter of 2025Ended the quart...

 PRESS RELEASE

Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Co...

Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time.  Event: Canaccor...

 PRESS RELEASE

Ceribell to Report Second Quarter 2025 Financial Results on August 5, ...

Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025 SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5, 2025. Investors int...

 PRESS RELEASE

Ceribell Files Complaints Against Natus Medical Incorporated with the ...

Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology SUNNYVALE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a leading medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that it filed complaints against Natus Medical Incorporated and related subsidiaries (“Natus”), alleging pat...

 PRESS RELEASE

Ceribell to Participate in the William Blair 45th Annual Growth Stock ...

Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.  Event: William...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch